1Kaplan JE,Benson C,Holmes KK,et al.Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:recommendations from CDC,the National Institutes of Health,and the HIV Medicine Association of the Infectious Diseases Society of America[J].MMWR Recomm Rep,2009,58(RR-4):1-207;quiz CE1-4.
3La Ferla L,Pinzone MR,Nunnari G,et al.Kaposi's sarcoma in HIV-positive patients:the state of art in the HAART-era[J].Eur Rev Med Pharmacol Sci,2013,17(17):2354-2365.
4Wu XJ,Pu XM,Kang XJ,et al.One hundred and five Kaposi sarcoma patients:a clinical study in Xinjiang,Northwest of China[J].J Eur Acad Dermatol Venereol,2014,28(11):1545-1552.
5Ruocco E,Ruocco V,Tornesello ML,et al.Kaposi's sarcoma:etiology and pathogenesis,inducing factors,causal associations,and treatments:facts and controversies[J].Clin Dermatol,2013,31(4):413-422.
6Hiatt KM,Nelson AM,Lichy JH,et al.Classic Kaposi Sarcoma in the United States over the last two decades:a clinicopathologic and molecular study of 438non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma[J].Modern pathology,2008,21(5):572-582.
7Robey RC,Bower M.Facing up to the ongoing challenge of Kaposi's sarcoma[J].Curr Opin Infect Dis,2015,28(1):31-40.
8Di Lorenzo G,Kreuter A,Di Trolio R,et al.Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma:a multicenter study[J].The Journal of investigative dermatology,2008,128(6):1578-1580.
9Régnier-Rosencher E,Guillot B,Dupin N.Treatments for classic Kaposi sarcoma:a systematic review of the literature[J].J Am Acad Dermatol,2013,68(2):313-331.
10Vincenzi B,Donofrio L,Frezza AM,et al.Classic Kaposi Sarcoma:to treat or not to treat?[J].BMC Res Notes,2015,8:138.
